Getinge AB (publ) (GETI-B.ST)
SEK 174.85
(2.01%)
SEK 174.85
(2.01%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 13.43 Billion SEK | 0.16% |
| 2022 | 13.4 Billion SEK | -1.26% |
| 2021 | 13.58 Billion SEK | -7.76% |
| 2020 | 14.72 Billion SEK | 18.2% |
| 2019 | 12.45 Billion SEK | 12.68% |
| 2018 | 11.05 Billion SEK | 4.25% |
| 2017 | 10.6 Billion SEK | -23.4% |
| 2016 | 13.84 Billion SEK | -2.28% |
| 2015 | 14.16 Billion SEK | 8.03% |
| 2014 | 13.11 Billion SEK | -0.11% |
| 2013 | 13.12 Billion SEK | 3.31% |
| 2012 | 12.7 Billion SEK | 11.42% |
| 2011 | 11.4 Billion SEK | 0.27% |
| 2010 | 11.37 Billion SEK | 1.06% |
| 2009 | 11.25 Billion SEK | 20.56% |
| 2008 | 9.33 Billion SEK | 17.56% |
| 2007 | 7.93 Billion SEK | 30.25% |
| 2006 | 6.09 Billion SEK | 11.66% |
| 2005 | 5.45 Billion SEK | 7.9% |
| 2004 | 5.05 Billion SEK | 22.94% |
| 2003 | 4.11 Billion SEK | 7.86% |
| 2002 | 3.81 Billion SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 3.65 Billion SEK | 8.06% |
| 2024 Q3 | 3.55 Billion SEK | -2.82% |
| 2024 Q1 | 3.38 Billion SEK | -15.56% |
| 2023 Q1 | 3.51 Billion SEK | -8.05% |
| 2023 Q4 | 4 Billion SEK | 11.64% |
| 2023 Q3 | 3.59 Billion SEK | 15.88% |
| 2023 Q2 | 3.09 Billion SEK | -11.94% |
| 2023 FY | 13.43 Billion SEK | 0.16% |
| 2022 Q2 | 3.14 Billion SEK | 3.14% |
| 2022 Q1 | 3.05 Billion SEK | -22.51% |
| 2022 FY | 13.4 Billion SEK | -1.26% |
| 2022 Q4 | 3.82 Billion SEK | 13.22% |
| 2022 Q3 | 3.38 Billion SEK | 7.34% |
| 2021 Q1 | 3.08 Billion SEK | -25.93% |
| 2021 FY | 13.58 Billion SEK | -7.76% |
| 2021 Q2 | 3.42 Billion SEK | 11.27% |
| 2021 Q3 | 3.13 Billion SEK | -8.58% |
| 2021 Q4 | 3.94 Billion SEK | 25.76% |
| 2020 Q3 | 4.13 Billion SEK | 19.43% |
| 2020 FY | 14.72 Billion SEK | 18.2% |
| 2020 Q2 | 3.45 Billion SEK | 16.2% |
| 2020 Q1 | 2.97 Billion SEK | -26.63% |
| 2020 Q4 | 4.15 Billion SEK | 0.68% |
| 2019 Q4 | 4.05 Billion SEK | 38.29% |
| 2019 Q3 | 2.93 Billion SEK | 2.23% |
| 2019 Q1 | 2.59 Billion SEK | -27.36% |
| 2019 FY | 12.45 Billion SEK | 12.68% |
| 2019 Q2 | 2.86 Billion SEK | 10.47% |
| 2018 Q3 | 2.42 Billion SEK | -8.82% |
| 2018 FY | 11.05 Billion SEK | 4.25% |
| 2018 Q1 | 2.4 Billion SEK | 261.5% |
| 2018 Q2 | 2.65 Billion SEK | 10.4% |
| 2018 Q4 | 3.57 Billion SEK | 47.73% |
| 2017 Q4 | 665 Million SEK | -79.17% |
| 2017 Q3 | 3.19 Billion SEK | -7.42% |
| 2017 FY | 10.6 Billion SEK | -23.4% |
| 2017 Q2 | 3.44 Billion SEK | 4.67% |
| 2017 Q1 | 3.29 Billion SEK | -24.89% |
| 2016 Q4 | 4.38 Billion SEK | 33.95% |
| 2016 Q1 | 3.01 Billion SEK | -32.34% |
| 2016 Q2 | 3.16 Billion SEK | 5.18% |
| 2016 FY | 13.84 Billion SEK | -2.28% |
| 2016 Q3 | 3.27 Billion SEK | 3.41% |
| 2015 FY | 14.16 Billion SEK | 8.03% |
| 2015 Q4 | 4.45 Billion SEK | 37.35% |
| 2015 Q3 | 3.24 Billion SEK | -2.73% |
| 2015 Q2 | 3.33 Billion SEK | 6.02% |
| 2015 Q1 | 3.14 Billion SEK | -25.24% |
| 2014 Q1 | 2.77 Billion SEK | -32.26% |
| 2014 FY | 13.11 Billion SEK | -0.11% |
| 2014 Q4 | 4.2 Billion SEK | 37.98% |
| 2014 Q3 | 3.04 Billion SEK | -1.2% |
| 2014 Q2 | 3.08 Billion SEK | 10.98% |
| 2013 Q4 | 4.1 Billion SEK | 38.83% |
| 2013 FY | 13.12 Billion SEK | 3.31% |
| 2013 Q3 | 2.95 Billion SEK | -5.38% |
| 2013 Q2 | 3.12 Billion SEK | 5.94% |
| 2013 Q1 | 2.94 Billion SEK | -26.76% |
| 2012 Q2 | 3 Billion SEK | 9.15% |
| 2012 Q3 | 2.92 Billion SEK | -2.86% |
| 2012 Q4 | 4.02 Billion SEK | 37.81% |
| 2012 FY | 12.7 Billion SEK | 11.42% |
| 2012 Q1 | 2.75 Billion SEK | -27.6% |
| 2011 Q3 | 2.53 Billion SEK | -2.09% |
| 2011 FY | 11.4 Billion SEK | 0.27% |
| 2011 Q1 | 2.48 Billion SEK | -27.47% |
| 2011 Q4 | 3.8 Billion SEK | 50.36% |
| 2011 Q2 | 2.58 Billion SEK | 4.03% |
| 2010 Q3 | 2.62 Billion SEK | -6.48% |
| 2010 Q2 | 2.8 Billion SEK | 11.91% |
| 2010 Q1 | 2.51 Billion SEK | -25.76% |
| 2010 FY | 11.37 Billion SEK | 1.06% |
| 2010 Q4 | 3.42 Billion SEK | 30.38% |
| 2009 FY | 11.25 Billion SEK | 20.56% |
| 2009 Q3 | 2.68 Billion SEK | 1.43% |
| 2009 Q4 | 3.38 Billion SEK | 25.73% |
| 2009 Q1 | 2.53 Billion SEK | 0.0% |
| 2009 Q2 | 2.65 Billion SEK | 4.74% |
| 2008 FY | 9.33 Billion SEK | 17.56% |
| 2007 FY | 7.93 Billion SEK | 30.25% |
| 2006 FY | 6.09 Billion SEK | 11.66% |
| 2005 FY | 5.45 Billion SEK | 7.9% |
| 2004 FY | 5.05 Billion SEK | 22.94% |
| 2003 FY | 4.11 Billion SEK | 7.86% |
| 2002 FY | 3.81 Billion SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -253458.618% |
| ADDvise Group AB (publ) | 300.6 Million SEK | -4368.064% |
| ADDvise Group AB (publ) | 300.6 Million SEK | -4368.064% |
| Arcoma AB | 11.07 Million SEK | -121216.954% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | -9494.874% |
| BICO Group AB (publ) | 1.83 Billion SEK | -633.694% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | -5278.553% |
| CellaVision AB (publ) | 463.04 Million SEK | -2800.607% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -448048.148% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 47368.819% |
| C-Rad AB (publ) | 66.01 Million SEK | -20245.376% |
| Duearity AB (publ) | -4.17 Million SEK | 321569.603% |
| Dignitana AB (publ) | 58.97 Million SEK | -22675.602% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 32231.579% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 26845.753% |
| Iconovo AB (publ) | 17.57 Million SEK | -76309.514% |
| Integrum AB (publ) | 690.56 Thousand SEK | -1944837.602% |
| Luxbright AB (publ) | -2.79 Million SEK | 480314.353% |
| Mentice AB (publ) | 236.38 Million SEK | -5581.929% |
| OssDsign AB (publ) | 83.64 Million SEK | -15957.146% |
| Paxman AB (publ) | 12.61 Million SEK | -106343.176% |
| Promimic AB (publ) | 38.51 Million SEK | -34772.128% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 26563.46% |
| SciBase Holding AB (publ) | 16.03 Million SEK | -83650.078% |
| ScandiDos AB (publ) | 47.55 Million SEK | -28143.087% |
| Sectra AB (publ) | 557.55 Million SEK | -2308.915% |
| Sedana Medical AB (publ) | 108.98 Million SEK | -12224.167% |
| Senzime AB (publ) | 8.33 Million SEK | -160962.478% |
| SpectraCure AB (publ) | -9.22 Million SEK | 145725.068% |
| Stille AB | 132.17 Million SEK | -10061.836% |
| Vitrolife AB (publ) | 1.97 Billion SEK | -579.019% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | -3121.535% |